The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Open accessAbstract
BACKGROUND: Mutations in RPE65 cause Leber's congenital amaurosis, a progressive retinal degenerative disease that severely impairs sight in children. Gene therapy can result in modest improvements in night vision, but knowledge of its efficacy in humans is limited. METHODS: We performed a phase 1-2 open-label trial involving 12 participants to evaluate the safety and efficacy of gene therapy with a recombinant adeno-associated virus 2/2 (rAAV2/2) vector carrying the RPE65 complementary DNA, and measured visual function over the course of 3 years. Four participants were administered a lower dose of the vector, and 8 were administered a higher dose. In a parallel study in dogs, we investigated the relationship among vector dose, visual function, and electroretinography (ERG) findings. RESULTS: Improvements in retinal sensitivity were evident, to varying extents, in six participants for up to 3 years, peaking at 6 to 12 months after treatment and then declining. No associated improvement in retinal function was detected by means of ERG. Three participants had intraocular inflammation, and two had clinically significant deterioration of visual acuity. The reduction in central retinal thickness varied among participants. In dogs, RPE65 gene therapy with the same vector at lower doses improved vision-guided behavior, but only higher doses resulted in improvements in retinal function that were detectable with the use of ERG. CONCLUSIONS: Gene therapy with rAAV2/2 RPE65 vector improved retinal sensitivity, albeit modestly and temporarily. Comparison with the results obtained in the dog model indicates that there is a species difference in the amount of RPE65 required to drive the visual cycle and that the demand for RPE65 in affected persons was not met to the extent required for a durable, robust effect. (Funded by the National Institute for Health Research and others; ClinicalTrials.gov number, NCT00643747.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ocular AAV therapies leading to a permanent reduction in visual acuity following intraocular inflammation (9–11)”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AAV dose-dependent intraocular inflammation and a few instances of persistent loss of visual acuity have been independently reported in clinical trials following subretinal AAV administration despite prophylactic immunosuppression (9–11).”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the phase 1/2 dose-escalation trials for RPE65-associated LCA, choroideremia, and retinitis pigmentosa GTPase regulator (RPGR)-associated X-linked retinitis pigmentosa, patients receiving higher doses of AAV have presented with various signs of retinal inflammation, including vitritis, retinitis, and choroiditis,2,6,7 implicating the presence of a cell-mediated immune response.”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite the perceived low immunogenicity of AAV and relative immune privilege of the intraocular environment,8 dose-dependent retinal inflammation, or gene therapy-associated uveitis (GTAU), has been observed in many retinal gene therapy trials, which limits the vector dose and therapeutic efficacy.”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite a 28-day oral corticosteroid therapy started 2 days before the first IVT, a regimen similar to that provided in several other clinical studies using IVT or sub-retinal AAV-based gene therapies,41–45 70.7% of lenadogene nolparvovec-treated eyes developed some degree of intraocular inflammation versus 10.2% of placebo-treated eyes.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [45]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is clinically important as intraocular inflammation could lead to irreversible loss of retinal cells, deterioration of visual function and reduced durability of treatment effect associated with a costly one-off treatment.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The intraocular inflammation is dose-dependent and can sometimes last for months or even years following treatment, leading to irreversible retinal structural damage and reduced visual function if uncontrolled (Bainbridge et al., 2015).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The intraocular inflammation is dose-dependent and can sometimes last for months or even years following treatment, leading to irreversible retinal structural damage and reduced visual function if uncontrolled (Bainbridge et al., 2015).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, one participant developed anterior uveitis at 2 weeks, followed by CRA and reduced visual acuity by 6 months.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two participants developed optic disc swelling, retinal vascular tortuosity/sheathing and mild vitritis.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three out of eight participants who received the higher dose of vector (1 × 10 12 vg/eye) but none in the lower dose cohort (1 × 10 11 vg/eye) developed intraocular inflammation despite prophylactic peri-operative immunosuppression.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, GTAU is often diagnosed shortly after the withdrawal of systemic immunosuppression prophy laxis (Dimopoulos et al., 2018) or when the dose reaches around 15 -20 mg for slower tapers, and sometimes several weeks to months after vector administration (Bainbridge et al., 2015).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although adeno-associated viral (AAV) vector-mediated retinal gene therapies have demonstrated efficacy”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [2]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The intraocular inflammation is dose-dependent and can sometimes last for months or even years following treatment, leading to irreversible retinal structural damage and reduced visual function if uncontrolled (Bainbridge et al., 2015).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredIn the citing paper
“In phase I/II clinical trials for RPE65-LCA at University College London (ClinicalTrials.gov: NCT00643747), ocular inflammation was noted following SRI of 1 × 1012 vg of AAV2-RPE65.71,99”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [99]
In the citing paper
“subfoveal viral gene therapy has been associated with various adverse effects, such as RPE alterations, retinal thinning, foveal morphological changes, vision loss, and the variable duration of clinical effects [281,294,296,297,298].”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [296]
In the citing paper
“Dose-dependent immune responses have also been observed, with high doses potentially leading to persistent inflammation and clinically significant vision loss in patients receiving high-dose AAV2 vector-based subretinal RPE65 therapy [296].”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [296]
In the citing paper
“However, some adverse events linked to the glucocorticoids themselves have already been described in retinal rAAV trials which point out the need for other alternatives to mitigate the inflammation [37].”
From Risk mitigation of immunogenicity: a key to personalized retinal gene therapy (2021) · cites this paper as [37]
In the citing paper
“The results showed that retinal sensitivity was improved; however, the final transgene expression in the participants from the high dose group was adversely affected by ocular inflammation or immune responses [48].”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [48]
In the citing paper
“Nonetheless, inflammatory reactions to gene therapy in the eye have led to permanent vision loss for some patients7–9.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hartong, D. T., Berson, E. L., & Dryja, T. P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69740-7 · Cited by 2,924
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Self-citationStatistics Notes: Measurement error
Bland, J. M., & Altman, D. G. (1996) · BMJ · doi:10.1136/bmj.313.7059.744 · Cited by 1,084
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Leber congenital amaurosis: Genes, proteins and disease mechanisms
den Hollander, A. I., Roepman, R., Koenekoop, R. K., & Cremers, F. P. M. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.003 · Cited by 811
Cideciyan, A. V., Alemán, T. S., Boye, S. L., Schwartz, S., Kaushal, S., Román, A. J., Pang, J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 674
Jacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
Research works printed but not linked: 3
- Poehner WJ, 2000, Mol Vis, 6, 192
- Geller SF, 2001, Invest Ophthalmol Vis Sci, 42, 1363
- 10.1056/NEJMoa1412965 · DOI
Cited by
Sorted by citations
Items 401–500 of 743
Recent advances and future challenges in gene therapy for hearing loss
Amariutei, A. E., Jeng, J., Safieddine, S., & Marcotti, W. (2023) · Royal Society Open Science · doi:10.1098/rsos.230644 · Cited by 22
Diagnostic application of clinical exome sequencing in Leber congenital amaurosis.
Han, J., Rim, J. H., Hwang, I. S., Kim, J., Shin, S., Lee, S., & Choi, J. R. (2017) · PubMed Central · Cited by 16
Psychosocial impacts of Mendelian eye conditions: A systematic literature review
D'Amanda, C. S., Nolen, R., Huryn, L. A., & Turriff, A. E. (2020) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2020.02.002 · Cited by 17
Taghian, T., Batista, A. R., Kamper, S. G., Caldwell, M. A., Lilley, L. M., Li, H., Rodríguez, P. M., Mesa, K., Zheng, S., King, R. M., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.08.003 · Cited by 16
Vision impairment after traumatic brain injury: present knowledge and future directions
Das, M., Tang, X., Mohapatra, S. S., & Mohapatra, S. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2018-0015 · Cited by 16
CRISPR-Cas Genome Surgery in Ophthalmology
DiCarlo, J. E., Sengillo, J. D., Justus, S., Cabral, T., Tsang, S. H., & Mahajan, V. B. (2017) · Translational Vision Science & Technology · doi:10.1167/tvst.6.3.13 · Cited by 15
The functional characteristics of optogenetic gene therapy for vision restoration
Lindner, M., Gilhooley, M. J., Peirson, S. N., Hughes, S., & Hankins, M. W. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03597-6 · Cited by 15
Ripamonti, C., Henning, G. B., Robbie, S. J., Sundaram, V., van den Born, L. I., Casteels, I., de Ravel, T. J. L., Moore, A. T., Smith, A. J., Bainbridge, J. W., et al. (2015) · Journal of Vision · doi:10.1167/15.15.20 · Cited by 15
Self-citationDesrosiers, M., & Dalkara, D. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7522-8_16 · Cited by 15
Sumaroka, A., Cideciyan, A. V., Charng, J., Wu, V. F., Powers, C. A., Iyer, B. S., Lisi, B., Świder, M., & Jacobson, S. G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215344 · Cited by 15
Nonhuman Primate Model of Oculocutaneous Albinism with TYR and OCA2 Mutations
Wu, K., Lv, J., Yang, H., Yang, F., Lin, R., Lin, Q., Shen, R., Wang, J., Duan, W., Hu, M., et al. (2020) · Research · doi:10.34133/2020/1658678 · Cited by 15
Foggia, V. D., Makwana, P., Ali, R. R., & Sowden, J. C. (2016) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2015.0143 · Cited by 15
Self-citationTyler, N. (2017) · IATSS Research · doi:10.1016/j.iatssr.2017.06.002 · Cited by 15
Self-citationKumaran, N., Robson, A. G., & Michaelides, M. (2018) · Retinal Cases & Brief Reports · doi:10.1097/icb.0000000000000754 · Cited by 15
Self-citationCreating an Ocular Biofactory: Surgical Approaches in Gene Therapy for Acquired Retinal Diseases
Xu, D. N., Khan, M., & Ho, A. C. (2021) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000362 · Cited by 19
van der Veen, I., Heredero Berzal, A., Koster, C., ten Asbroek, A. L. M. A., Bergen, A. A., & Boon, C. J. F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021267 · Cited by 14
van Schuppen, S. M., Talib, M., Bergen, A. A. B., ten Brink, J. B., Florijn, R. J., Boon, C. J. F., & van Schooneveld, M. J. (2017) · Retina · doi:10.1097/iae.0000000000001844 · Cited by 14
Fine-tuning FAM161A gene augmentation therapy to restore retinal function
Arsenijévic, Y., Chang, N., Mercey, O., Fersioui, Y. E., Koskiniemi-Kuendig, H., Joubert, C., Bemelmans, A., Rivolta, C., Banin, E., Sharon, D., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00053-x · Cited by 15
Nolan, N. D., Cui, X., Robbings, B. M., Demirkol, A., Pandey, K., Wu, W.-H., Hu, H. F., Jenny, L. A., Lin, C., Hass, D. T., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101459 · Cited by 19
Long-term Nerve Regeneration in Diabetic Keratopathy Mediated by a Novel NGF Delivery System
Cong, L., Qi, B., Chen, S., Liu, R., Li, S., Zhou, Q., Cao, Y., Zhang, B. N., & Xie, L. (2024) · Diabetes · doi:10.2337/db24-0393 · Cited by 14
Li, H., Li, Q., Zhang, X., Zheng, X., Zhang, Q., & Hao, Z. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3043 · Cited by 14
The role of gap junctions in cell death and neuromodulation in the retina
Szarka, G., Balogh, M., Tengölics, Á. J., Ganczer, A., Völgyi, B., & Kovács‐Öller, T. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.308069 · Cited by 16
Therapeutic avenues for hereditary forms of retinal blindness
Kannabiran, C., & Mariappan, I. (2018) · Journal of Genetics · doi:10.1007/s12041-017-0880-x · Cited by 14
Night-vision aid using see-through display for patients with retinitis pigmentosa
Ikeda, Y., Nakatake, S., Funatsu, J., Fujiwara, K., Tachibana, T., Murakami, Y., Hisatomi, T., Yoshida, S., Enaida, H., Ishibashi, T., et al. (2019) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-018-00644-5 · Cited by 14
The clinical safety landscape for ocular AAV gene therapies: A systematic review and meta-analysis
Liu, Z., Zhang, H., Jia, H., Wang, H., Huang, Z., Tang, Y., Wang, Z., Hu, J., Zhao, X., Li, T., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112265 · Cited by 15
Jia, R., Chen, S., Wang, L., Zhang, J., Qu, B., Qiao, J., Meng, X., Yu, S., Liu, X., Xu, B., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101377 · Cited by 15
Zhai, Y., Xu, M., Radziwon, A., Dimopoulos, I. S., Crichton, P., Mah, R. A., MacLaren, R. E., Somani, R., TENNANT, M. T. S., & MacDonald, I. M. (2022) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.12.022 · Cited by 13
Kistner, A., Chichester, J. A., Wang, L., Calcedo, R., Greig, J. A., Cardwell, L. N., Wright, M. C., Couthouis, J., Sethi, S., McIntosh, B. E., et al. (2023) · Gene Therapy · doi:10.1038/s41434-023-00423-z · Cited by 13
Muñoz-Melero, M., & Biswas, M. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.227 · Cited by 14
Genetic therapies and potential therapeutic applications of CRISPR activators in the eye
Ng, B., Kaukonen, M. K., McClements, M. E., Shamsnajafabadi, H., MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101289 · Cited by 13
Au, E. D., Fernández‐Godino, R., Kaczynksi, T. J., Sousa, M. E., & Farkas, M. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183939 · Cited by 11
Limited time window for retinal gene therapy in a preclinical model of ciliopathy
Datta, P., Ruffcorn, A., & Seo, S. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa124 · Cited by 13
Visual Cortex Plasticity Following Peripheral Damage To The Visual System: fMRI Evidence
Lemos, J., Pereira, D. J., & Castelo-Branco, M. S. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-016-0691-0 · Cited by 14
Li, P., Boenzli, E., Hofmann‐Lehmann, R., & Helfer-Hungerbuehler, A. K. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212811 · Cited by 14
Deletion of M-Opsin Prevents M Cone Degeneration in a Mouse Model of Leber Congenital Amaurosis
Xu, H., Enemchukwu, N. O., Zhong, X., Zhang, O., & Fu, Y. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.01.005 · Cited by 13
Stiff, H. A., Sloan-Heggen, C., Ko, A., Pfeifer, W. L., Kolbe, D. L., Nishimura, C. J., Frees, K. L., Booth, K. T. A., Wang, D., Weaver, A. E., et al. (2020) · Ophthalmic Genetics · doi:10.1080/13816810.2020.1747088 · Cited by 13
Ross, M., Obolensky, A., Averbukh, E., Desrosiers, M., Ezra-Elia, R., Honig, H., Yamin, E., Rosov, A., Dvir, H., Gootwine, E., et al. (2022) · Gene Therapy · doi:10.1038/s41434-021-00306-1 · Cited by 13
RPE based gene and cell therapy for inherited retinal diseases: A review
Sanie‐Jahromi, F., & Nowroozzadeh, M. H. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2022.108961 · Cited by 13
Wu, F., He, W., Xiao, Y., Wu, Q., Zhang, Q., Zhang, T., Xu, L., & Pang, X. (2025) · Advanced Science · doi:10.1002/advs.202408397 · Cited by 12
From Bench to Bed: The Current Genome Editing Therapies for Glaucoma
He, M., Rong, R., Ji, D., & Xia, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.879957 · Cited by 13
Kick, G. R., Whiting, R. E. H., Ota‐Kuroki, J., Castaner, L. J., Morgan-Jack, B. R., Sabol, J. C., Meiman, E. J., Ortiz, F., & Katz, M. L. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2022.109344 · Cited by 12
Genome Editing in Retinal Diseases using CRISPR Technology
Yiu, G. C. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.09.015 · Cited by 12
CRISPRi-Mediated Treatment of Dominant Rhodopsin-Associated Retinitis Pigmentosa
Burnight, E. R., Wiley, L. A., Mullin, N. K., Adur, M. K., Lang, M. J., Cranston, C. M., Jiao, C., Russell, S. R., Sohn, E. H., Han, I. C., et al. (2023) · The CRISPR Journal · doi:10.1089/crispr.2023.0039 · Cited by 11
Diagnosis and Complementary Examinations
Menghini, M., & Duncan, J. L. (2014) · Developments in ophthalmology · doi:10.1159/000357324 · Cited by 11
Available Evidence on Leber Congenital Amaurosis and Gene Therapy
Alkharashi, M., & Fulton, A. B. (2016) · Seminars in Ophthalmology · doi:10.1080/08820538.2016.1228383 · Cited by 11
Iatrogenic choroidal neovascularization associated with subretinal gene therapy surgery
Price, K. W., Pennesi, M. E., Lauer, A. K., & Bailey, S. T. (2022) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2022.101677 · Cited by 11
Gene therapy approaches for the treatment of retinal disorders.
Petit, L., & Punzo, C. (2016) · PubMed · Cited by 11
Retinal structure in Leber’s congenital amaurosis caused by RPGRIP1 mutations
Miyamichi, D., Nishina, S., Hosono, K., Yokoi, T., Kurata, K., Sato, M., Hotta, Y., & Azuma, N. (2019) · Human Genome Variation · doi:10.1038/s41439-019-0064-8 · Cited by 11
Gene therapy development in hearing research in China
Zhang, Z., Wang, J., Li, C., Xue, W., Xing, Y., & Liu, F. (2020) · Gene Therapy · doi:10.1038/s41434-020-0177-1 · Cited by 11
Rodríguez‐Bocanegra, E., Wozar, F., Seitz, I. P., Reichel, F. F., Ochakovski, G. A., Bucher, K., Wilhelm, B., Bartz‐Schmidt, K. U., Peters, T. M., & Fischer, M. D. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.6.15 · Cited by 11
Intrinsic and Induced Neuronal Regeneration in the Mammalian Retina
Woodworth, M. B., Greig, L. C., & Goldberg, J. L. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0309 · Cited by 10
Ocular manifestations of renal ciliopathies
Salehi, O., Mack, H. G., Colville, D. J., Lewis, D. A., & Savige, J. (2023) · Pediatric Nephrology · doi:10.1007/s00467-023-06096-5 · Cited by 11
AAV2-antiVEGFscFv gene therapy for retinal neovascularization
Han, N., Xu, X., Liu, Y., & Luo, G. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101145 · Cited by 10
Sauter, M. M., Noel, H. R., Sinha, D., Nelson, E. C., Xiong, M. N., Gamm, D. M., & Brandt, C. R. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110478 · Cited by 10
Udry, F., Decembrini, S., Gamm, D. M., Déglon, N., Kostic, C., & Arsenijévic, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-65657-y · Cited by 10
A Comprehensive Study of the Retinal Phenotype of Rpe65-Deficient Dogs
Annear, M. J., Mowat, F. M., Occelli, L. M., Smith, A. J., Curran, P. G., Bainbridge, J. W., Ali, R. R., & Petersen‐Jones, S. M. (2021) · Cells · doi:10.3390/cells10010115 · Cited by 11
Self-citationRosa, R. H., Xie, W., Zhao, M., Tsai, S., Roddy, G. W., Su, M. G., Potts, L. B., Hein, T. W., & Kuo, L. (2022) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.03.014 · Cited by 13
Progress and prospects of gene therapy in ophthalmology from 2000 to 2022: A bibliometric analysis
Li, B., Tan, W., Wang, Z., Zhou, H., Zou, J., Li, Y., Yoshida, S., & Zhou, Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18228 · Cited by 12
Combes, R. D., & Shah, A. B. (2016) · Alternatives to Laboratory Animals · doi:10.1177/026119291604400302 · Cited by 11
Recording and Analysis of Goldmann Kinetic Visual Fields
Talib, M., Dagnelie, G., & Boon, C. J. F. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7522-8_24 · Cited by 10
Russell, S. R., Bennett, J., Maguire, A. M., & High, K. A. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1508340 · Cited by 10
Biopolymers augment viral vectors based gene delivery
Balakrishnan, B., & David, E. (2019) · Journal of Biosciences · doi:10.1007/s12038-019-9905-3 · Cited by 10
Peripapillary Intravitreal Injection Improves AAV-Mediated Retinal Transduction
Madrakhimov, S. B., Yang, J. Y., Ahn, D. H., Han, J. W., Ha, T. H., & Park, T. K. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.018 · Cited by 10
Mbefo, M. K., Berger, A., Schouwey, K., Gérard, X., Kostic, C., Beryozkin, A., Sharon, D., Dolfuss, H., Munier, F. L., Tran, H. V., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179331 · Cited by 10
Piotter, E., McClements, M. E., & MacLaren, R. E. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.814131 · Cited by 11
Gene therapy for the long term treatment of wet AMD
Rakoczy, E. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31262-x · Cited by 10
Genome editing: the breakthrough technology for inherited retinal disease?
Smith, A. J., Carter, S. P., & Kennedy, B. N. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1347629 · Cited by 10
Self-citationRevival of Bioengineered Proteins as Carriers for Nucleic Acids
Scherer, D., Burger, M., & Leroux, J. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00079 · Cited by 10
Fischer, M. D. (2016) · Ophthalmologica · doi:10.1159/000445782 · Cited by 9
Clustered Regularly Interspaced Short Palindromic Repeats
Chrenek, M. A., Nickerson, J. M., & Boatright, J. H. (2016) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000225 · Cited by 9
Thompson, J. A., Roach, J. N. D., McLaren, T. L., & Lamey, T. M. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-75402-4_32 · Cited by 9
The clinical implications of molecular monitoring and analyses of inherited retinal diseases
Chacon-Camacho, O. F., García‐Montaño, L. A., & Zenteno, J. C. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1384314 · Cited by 8
Membrane fusion FerA domains enhance adeno-associated virus vector transduction
Zhang, X., Anthony, B., Chai, Z., Dobbins, A. L., Sutton, R. B., & Li, C. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119906 · Cited by 9
Mack, H. G., Chen, F. K., Grigg, J., Jamieson, R. V., Roach, J. N. D., O’Hare, F., Britten‐Jones, A. C., McGuinness, M. B., Tindill, N., & Ayton, L. N. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-048361 · Cited by 10
Bellingrath, J.-S., McClements, M. E., Kaukonen, M. K., Fischer, M. D., & MacLaren, R. E. (2021) · Genes · doi:10.3390/genes12121908 · Cited by 9
AAVLINK: A potent DNA-recombination method for large cargo delivery in gene therapy
Lin, J., Lin, Y., Liu, N., Cao, W., Zhang, J., Wen, S., Zhang, Y., Liao, W., Hong, Z., Lin, Y., et al. (2026) · Cell · doi:10.1016/j.cell.2025.12.039 · Cited by 12
Consensus guidelines for nomenclature of companion animal inherited retinal disorders
Mowat, F. M., Iwabe, S., Aguirre, G. D., & Petersen‐Jones, S. M. (2024) · Veterinary Ophthalmology · doi:10.1111/vop.13185 · Cited by 8
Self-citationEpigenetic editing for autosomal dominant neurological disorders
Waldo, J. J., Halmai, J. A. N. M., & Fink, K. D. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1304110 · Cited by 8
Dong, Y., Cai, X., Wu, Y., Liu, Y., Deng, L., & Chen, H. (2017) · PubMed · Cited by 8
Nishiguchi, K. M., Fujita, K., Tokashiki, N., Komamura, H., Takemoto‐Kimura, S., Okuno, H., Bito, H., & Nakazawa, T. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.012 · Cited by 8
Oh, A., Loew, E. R., Foster, M. L., Davidson, M. G., English, R. V., Gervais, K. J., Herring, I. P., & Mowat, F. M. (2018) · Documenta Ophthalmologica · doi:10.1007/s10633-018-9653-y · Cited by 8
Self-citationIt’s never too late to save a photoreceptor
Hurley, J. B., & Chao, J. R. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83194 · Cited by 8
Precision assessment of public attitudes toward genetic testing
Shen, J. (2016) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.37936 · Cited by 8
Retinal vessel oximetry in children with inherited retinal diseases
Waizel, M. D. V., Scholl, H. P. N., Valmaggia, C., & Todorova, M. G. (2020) · Acta Ophthalmologica · doi:10.1111/aos.14466 · Cited by 8
Yu, D. L., Chow, N., & Wootton, S. K. (2020) · Viruses · doi:10.3390/v12111266 · Cited by 8
DGK and DZHK position paper on genome editing: basic science applications and future perspective
Brandes, R. P., Dueck, A., Engelhardt, S. H., Kaulich, M., Kupatt, C., Angelis, M. T. D., Leisegang, M. S., le Noble, F. A. C., Moretti, A., Müller, O. J., et al. (2021) · Basic Research in Cardiology · doi:10.1007/s00395-020-00839-3 · Cited by 8
Feasibility of direct vitrectomy-sparing subretinal injection for gene delivery in large animals
Stranak, Z., Ardan, T., Nemesh, Y., Toms, M., Toualbi, L., Harbottle, R., Ellederova, Z., Lytvynchuk, L., Petrovski, G., Motlik, J., et al. (2024) · Current Eye Research · doi:10.1080/02713683.2024.2343335 · Cited by 7
AAV-mediated expression of proneural factors stimulates neurogenesis from adult Müller glia in vivo
Pavlou, M., Probst, M., Kaplan, L., Filippova, E., Prieve, A., Rieke, F. M., & Reh, T. A. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00209-3 · Cited by 16
Zeng, L., Wei, Y., Qiu, Y., Bi, R., Peng, H., Hu, B., & Li, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s521960 · Cited by 7
Ren, C., Song, L., Hu, M., Jin, X., Liang, L., Liu, F., Su, J., Fu, J., Yang, Y., Liu, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66176-y · Cited by 8
Torii, K., Nishina, S., Morikawa, H., Mizobuchi, K., Takayama, M., Tachibana, N., Kurata, K., Hikoya, A., Sato, M., Nakano, T., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813678 · Cited by 7
Jiang, F., Zhang, C., Liu, W., Liu, F., Huang, H., Tan, Y. F., & Qin, B. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1301915 · Cited by 9
Gene therapy: Myth or reality?
Fischer, A. (2016) · Comptes Rendus Biologies · doi:10.1016/j.crvi.2016.04.011 · Cited by 10
Artificial vision: principles and prospects
Gilhooley, M. J., & Acheson, J. F. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000412 · Cited by 7
Novel non‐contiguous exon duplication in choroideremia
Edwards, T. L., Williams, J. P., Patrício, M. I., Simunovic, M. P., Shanks, M. E., Clouston, P., & MacLaren, R. E. (2017) · Clinical Genetics · doi:10.1111/cge.13021 · Cited by 7
Omari, A. A., Niziol, L. M., & Gardner, T. W. (2019) · Acta Ophthalmologica · doi:10.1111/aos.14097 · Cited by 7
Li, S., Gordon, W. C., Bazan, N. G., & Jin, M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012623117 · Cited by 7
Jauregui, R., Parmann, R., Nuzbrokh, Y., Tsang, S. H., & Sparrow, J. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-93316-3 · Cited by 7
Occelli, L. M., Marinho, F. P., Singh, R. K., Binette, F., Nasonkin, I. O., & Petersen‐Jones, S. M. (2021) · Journal of Visualized Experiments · doi:10.3791/61683 · Cited by 7
Self-citationHan, I. C., Burnight, E. R., Kaalberg, E. E., Boyce, T. M., Stone, E. M., Fingert, J. H., Mullins, R. F., Tucker, B. A., & Wiley, L. A. (2021) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2021.0057 · Cited by 7
Metadata
- Authors
- Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., Feathers, K. L., Luong, V. A., Yzer, S., Balaggan, K., Viswanathan, A., de Ravel, T. J. L., Casteels, I., Holder, G. E., Tyler, N., Fitzke, F. W., Weleber, R. G., Nardini, M., Moore, A. T., Thompson, D. A., Petersen-Jones, S. M., Michaelides, M., van den Born, L. I., Stockman, A., Smith, A. J., Rubin, G., & Ali, R. R.
- Affiliations
- Moorfields Eye Hospital (GB)
- Michigan State University (US)
- University of Michigan (US)
- Rotterdam Eye Hospital (NL)
- Universitair Ziekenhuis Leuven (BE)
- Oregon Health & Science University (US)
- ORCID
- Bainbridge, James W.B.
- Sundaram, Venki
- Robbie, Scott J.
- Georgiadis, Anastasios
- Mowat, Freya M.
- Beattie, Stuart G.
- Yzer, Suzanne
- Balaggan, Kamaljit
- Viswanathan, Ananth
- Casteels, Ingele
- Holder, Graham E.
- Tyler, Nick
- Weleber, Richard G.
- Moore, Anthony T.
- Thompson, Debra A.
- Michaelides, Michel
- Smith, Alexander J.
- Rubin, Gary
- Ali, Robin R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-14
- Volume
- 372
- Issue
- 20
- Pages
- 1887-1897
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4497809
- OpenAlex
- W265142245
- Semantic Scholar
- 31832b3aa3500171fc5f2a951f0a4124bd40068d
- Cited by
- 743
- References
- 29
- Citations by year
- 2026: 36 · 2025: 36 · 2024: 46 · 2023: 44 · 2022: 63 · 2021: 92 · 2020: 81 · 2019: 68 · 2018: 79 · 2017: 97 · 2016: 72 · 2015: 27
- FWCI
- 39.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Durham Research Online (Durham University) (acceptedVersion)
- Durham Research Online (Durham University) (submittedVersion, cc-by)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Research to Prevent Blindness
- Wellcome Trust
- Massachusetts Medical Society
- National Institute for Health and Care Research (NF-SI-0507-10204, NF-SI-0513-10074, NIHR-RP-011-003)
- Sir Jules Thorn Charitable Trust
- University College London
- European Commission
- Ulverscroft Foundation
- Durham University
- KU Leuven
- Moorfields Eye Hospital NHS Foundation Trust
- Directorate for Biological Sciences
- Medical Research Council (MR/K024000/1, MR/M015815/1, MR/J005215/1)
- Engineering and Physical Sciences Research Council (EP/J017698/1, EP/J005193/1)
- Biotechnology and Biological Sciences Research Council (BB/M00211X/1)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- Leber congenital amaurosis, RPE65, gene therapy, retinal degeneration, visual function, retinal sensitivity, electroretinogram, vector dose, intraocular inflammation, visual acuity, canine model, species differences, long-term efficacy and safety
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Adolescent, Animals, Child, Disease Models, Animal, Dogs, Genetic Vectors, Humans, Mutation, Retina, Vision, Ocular, Genetic Therapy, DNA, Complementary, Disease Progression, cis-trans-Isomerases, Photoreceptor Cells, Vertebrate, Young Adult, Leber Congenital Amaurosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
